UK Cannabis Laws: The Political Corruption Exposed

The story of UK cannabis law is not merely a tale of misguided policy or cultural conservatism. It is a story of corruption — of politicians leveraging public office for private gain, of pharmaceutical companies capturing the regulatory apparatus, and of a system designed to suppress a natural medicine in favour of corporate profits. The evidence is not circumstantial. It is documented, reported, and publicly available for anyone willing to follow the trail.

The British Sugar Connection

Victoria Atkins served as the UK Minister for Crime, Safeguarding and Vulnerability from 2017 to 2020, and later as the Minister for Prisons and Probation. In these roles, she had direct responsibility for drug policy, including the classification of cannabis and the enforcement of drug laws. She was also in a relationship with, and later married to, Paul Kenward, the managing director of British Sugar, a subsidiary of Associated British Foods.

British Sugar is a major manufacturer of sugar-based products used in the food and beverage industry. But the connection to cannabis policy is more direct than it first appears. British Sugar is also a producer of ethanol — the psychoactive component of alcoholic beverages. The company's interests align with maintaining the legal status quo, in which a legal, heavily taxed alcohol industry competes against an illegal cannabis market.

The Independent reported in 2018 that Atkins faced accusations of a conflict of interest for failing to declare her relationship with Kenward during parliamentary debates on drug policy ( [The Independent, 2018: Victoria Atkins Accused of Conflict of Interest]). Atkins voted against a motion to decriminalise cannabis for personal use while potentially benefiting, through her partner's employment, from the continued prohibition of the plant.

Philip May and Capital Group

Philip May — the husband of former Prime Minister Theresa May — worked for Capital Group, one of the world's largest investment management firms. Capital Group held significant investments in pharmaceutical companies, including GW Pharmaceuticals, the British company that held a virtual monopoly on medical cannabis production in the UK following the 2018 law change.

The timing is notable. Theresa May's government announced the rescheduling of cannabis-based medicinal products in 2018, following a series of high-profile cases involving children with severe epilepsy whose families had fought for access to cannabis oil. While the reform was genuinely supported by many campaigners, the specific regulatory framework that emerged appeared designed to benefit GW Pharmaceuticals at the expense of patients and smaller competitors.

The New Economic Foundation reported in 2021 that the pharmaceutical industry, including companies connected to Capital Group's portfolio, had disproportionately influenced the design of the UK medical cannabis regulatory framework ( [Left Foot Forward, 2021: The Pharma Links Behind the UK's Medical Cannabis Regulations]). Under the regulations, patients could access cannabis-based products only through specialist doctors on the General Medical Council's specialist register, severely limiting availability and channelling patients towards expensive pharmaceutical products rather than natural whole-plant medicines.

The GW Pharma Monopoly

GW Pharmaceuticals, founded in 1998, developed Sativex, a cannabis-derived oromucosal spray containing equal ratios of THC and CBD, and Epidiolex, a purified CBD formulation for childhood epilepsy. The company held dozens of patents covering cannabis-based medicines, including patents on the methods of extraction, formulation, and administration that effectively blocked competitors from entering the market.

The regulatory framework that emerged in the UK after 2018 was, critics argued, essentially designed around GW's product portfolio. By requiring cannabis-based products to meet the same standards as conventional pharmaceuticals — including expensive clinical trials, manufacturing standards, and marketing authorisations — the system effectively locked out whole-plant cannabis medicines and created a barrier to entry that only well-capitalised pharmaceutical companies could surmount.

This was not an accident. The pharmaceutical industry had spent decades and millions of pounds lobbying for a regulatory framework that would treat cannabis as a patentable medicine rather than a natural plant. The result was a system that gave GW Pharmaceuticals a first-mover monopoly while criminalising everyone who attempted to grow, possess, or consume cannabis outside the pharmaceutical supply chain.

The $7.2 Billion Jazz Acquisition

In 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals for $7.2 billion ( [MJBizDaily, 2021: Jazz Pharmaceuticals Acquires GW Pharma for $7.2 Billion]). The acquisition marked one of the largest exits in the history of the cannabis industry and delivered enormous returns to GW's shareholders — including, potentially, the investment funds managed by Capital Group.

The $7.2 billion price tag is a measure of the value of monopoly. GW Pharmaceuticals was not a £7 billion company because it had invented a uniquely effective medicine. It was a £7 billion company because it had successfully captured the regulatory apparatus of the United Kingdom and used it to exclude competition. The value of GW's patents was inseparable from the value of the legal prohibition that made them enforceable.

This is the ultimate scandal of UK cannabis law. The prohibition that has devastated hundreds of thousands of lives — that has criminalised patients, filled prisons, and enriched organised crime — has also enriched the very people who wrote the laws. The politicians who vote for prohibition have financial connections to the industries that benefit from it. The pharmaceutical companies that lobby for a restricted market are rewarded with monopoly profits. And the ordinary citizens who use cannabis — whether for medicine or recreation — are treated as criminals.

The exposure of these connections does not prove that every politician who voted for prohibition was personally corrupt. But it does demonstrate that the system itself is corrupt — that the legal framework governing cannabis in the United Kingdom was designed, whether consciously or not, to serve the financial interests of the powerful at the expense of the public good. The only question that remains is whether the public will continue to tolerate it.

Read more: Political Corruption in UK Cannabis Policy →